Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen
focus, meet competition
[September 10, 2025]
FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo
Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut
9,000 jobs, 5,000 of them in Denmark, in order to strengthen the
company's focus on growth opportunities in obesity and diabetes
medications.
The restructuring, which would eliminate 11% of the company's workforce,
aimed to reduce organizational complexity and speed up decision-making
as the company faces a more competitive market for obesity drugs.
The streamlining would save 8 billion Danish krone ($1.25 billion) by
the end of 2026, savings that are to be redirected to diabetes and
obesity, including research and development, the company said. Novo
Nordisk also makes Ozempic, a diabetes drug that also can result in
weight loss.
The company said implementation of the job cuts would begin immediately
and that it would let the affected employees know over the next few
months depending on local labor rules. The company, which is based in
Bagsvaerd just outside Copenhagen, has 78,400 workers.
[to top of second column]
|
 “Our markets are evolving,
particularly in obesity, as it has become more competitive and
consumer-driven,” said President and CEO Mike Doustdar. "Our company
must evolve as well. This means instilling an increased
performance-based culture, deploying our resources ever more
effectively, and prioritizing investment where it will have the most
impact — behind our leading therapy areas.”
Doustdar became CEO in May after his predecessor,
Lars Fruergaard Jorgensen, left the company after the share price
fell and as the company faced competition from weight-loss drugs
from competitor Eli Lilly. Shares had skyrocketed after the
introduction of Wegovy and Ozempic, which are both based on the same
basic ingredient, semaglutide.
At the peak, the company’s market capitalization — or the combined
price of all its shares — exceeded Denmark’s annual gross domestic
product and made it Europe’s most valuable company.
All contents © copyright 2025 Associated Press. All rights reserved |
